NewsRoom Articles - Page 16 of 45

WednesdayOct 18, 2023 9:00 am

Jewelry Maker GEMXX Corp. (GEMZ) Notes Growing Success in Quarterly Financial Statement

Las Vegas-based jewelry maker GEMXX Corporation is reporting positive net revenues, and $0.00 in long-term liabilities, in the company’s recently released quarterly financial statement GEMXX is unique in that it mines its own gold resources and is making plans to operate the world’s largest Ammolite gemstone mine soon, all for its distinctively iridescent jewelry products Ammolite is a gemstone derived from the fossilized shells of large, extinct marine nautiluses — commercially mined in Alberta, Canada, and nowhere else in the world The company has a fully qualified Tier 1, Form 1A registration to raise up to $6 million through its…

MondayOct 16, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs

Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022 Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH Lexaria Bioscience (NASDAQ: LEXX), a…

MondayOct 09, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Announces Strong Financial Results for Second Quarter of 2023

Fr8Tech demonstrated steady growth in Q2 2023 reporting a 29% increase in revenue and a 93% rise in margin compared to 2022 reporting The company projects that it will hit revenues up to $42 million in 2023 – an increase over the previous year at approximately $27 million Fr8Tech offers technology solutions that include a freight matching platform for OTR shipping internationally, a dedicated truck services and operations platform, and an LTL freight matching platform in Mexico Fr8Tech continues to dedicate its offering to innovative solutions that enhance and innovate the transportation industry and simplify and optimize supply chain processes…

FridayOct 06, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Pushing for Efficient Commerce Amid Developing Driverless Truck Legislation

FRGT, through its growing suite of solutions, is proving to be a formidable B2B cross-border shipping player in the NAFTA region Its ambitious efforts have seen the company join AMACARGA while also integrating with Samsara and collaborating with Trucker Tools By doing so, FRGT is helping the freight transportation marketplace to move commerce efficiently Freight Technologies (NASDAQ: FRGT), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, remains committed to helping the freight transportation marketplace to move commerce efficiently. Its recent push for its load-matching solution…

WednesdayOct 04, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Helps Facilitate Cross-border Trade Amid Growing U.S. Nearshoring Trend in Mexico

Mexico has become the United States’ leading international trading partner in recent months amid the country’s ongoing trade war with China Coincidental with Mexico’s growth as a nearshore commercial trade partner, the port at Laredo, Texas has become the most lucrative hub for cross-border commerce, recording $28.1 billion during this year’s first quarter Freight Technologies (aka Fr8Tech) is dedicated to aiding cross-border commerce through a suite of technological solutions targeting the relatively unorganized cross-border shipping and carrier industry Fr8Tech’s flagship platform, Fr8App, draws on artificial intelligence and machine learning technology to help match loads optimally and monitor shipments from origin…

FridaySep 29, 2023 10:30 am

GEMXX Corp. (GEMZ) Plans 300% YoY Expansion in Gemstone and Jewelry Production to Meet Growing Demand

GEMXX is a mine-to-market enterprise that specializes in the production and distribution of gemstones, like Ammolite, and jewelry on a global scale Ammolite is a rare gemstone that exhibits a unique iridescence and is only found in southern Alberta, Canada The company recently announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is growing exponentially GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand Its shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months Although officially recognized…

FridaySep 29, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral…

ThursdaySep 28, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11% RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products…

TuesdaySep 26, 2023 9:00 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027 RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for…

MondaySep 25, 2023 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent The company has stated that…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000